Organizer's

Oct. 13 (Thu.) ,2016 09:30-11:30

Annex Hall
F201

Simultaneous Interpretation

Innovative Research Strategy in Global Pharmaceutical Companies

The research process and targets in the drug discovery has been changing under the environment in which big data derived from gene analysis by NGS, supercomputer and artificial intelligence have become important information for drug discovery. Efforts as represented by Precision Medicine Initiative are expected to progress understanding of how gene information, environmental factors and life style relate with health and development of diseases. In addition, some new research modalities such as iPS cells and digital medicine could realize paradigm shift in treatment of diseases. In order to generate innovative drug and treatments, pharmaceutical companies are required to establish unique research strength by pursuing synergy between internal research and external collaboration. In this seminar, some global pharmaceutical companies show us their current research focus as well as their future research strategy.

Cordinator

Yoshinori Ikeura

Chairman, R&D Committee, Japan Pharmaceutical Manufacturers Association / SRC (Shonan) Site Head & Head of General Manager Office, Pharmaceutical Research Division, Takeda Pharmaceutical

Evolving Trends in Precision Medicine

Mann Fung

Vice President, Oncology Innovation, Johnson and Johnson Innovation Center

RNA Therapeutics: Harnessing the Potential of Locked Nucleic Acid

Bo Rode Hansen

Global Head of RNA Therapeutics Research, Roche Pharma Research and Early Development, General Manager, Roche Innovation Center Copenhagen

Regenerative Medicine; the Astellas Approach

Tomonobu Koizumi

Vice President, Drug Discovery Research, Regenerative Medicine Labs., Astellas Pharmaceutical

The Frontiers of Innovative Drug Development Against Rare Diseases: Caveats, Issues and Paths Forward

Yuji Sato

Corporate Officer, Head of Japan R&D, Sanofi

Close Window